Co-Diagnostics share price logo

Co-Diagnostics

NASDAQ: CODX

$0.72

-0.04

(-5.81%)

as on

Co-Diagnostics Stock Performance

as on October 16, 2026 at 6:59 am IST

  • Day's High

    $0.72
    $0.81

    12.50%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.75
    $46.50
    downward going graph

    -3.61%

    Downside

    6358.33%

    Upside

    downward going graph

Co-Diagnostics share price movements today

Previous Close
$0.76
Open
$0.80
Volume
536.7K
Market Cap
$6.5M
Day's Low - High
$0.72 - $0.81
52 Week Low - High
$0.75 - $46.50

Co-Diagnostics Historical Returns

1 Month Return
-32.94 %
3 Month Return
-69.3 %
1 Year Return
-93.36 %
3 Year Return
-97.6 %
5 Year Return
-99.7 %

Co-Diagnostics Stock Fundamentals & Key Indicators

Check Co-Diagnostics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$6.5M

EPS (TTM)

-26.72

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.31%

PE Ratio (TTM)

-0.04

Industry PE ratio

-2.20

PEG Ratio

-0.00

EBITDA

-47.5M

Revenue (TTM)

721.4K

Profit Margin

8.07%

Return On Equity TTM

-210.99%

Co-Diagnostics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Co-Diagnostics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Co-Diagnostics image
Co-Diagnostics
Hold$6.5M-99.70%-0.048.07%0.00%
Medtronic image
Medtronic
Buy$117.6B-26.24%21.6366.69%3.07%
Edwards Lifesciences image
Edwards Lifesciences
Buy$49.1B-22.92%49.0177.98%0.00%
Abbott Laboratories image
Abbott Laboratories
StrongBuy$176.2B-12.36%33.0156.80%2.42%
Stryker image
Stryker
StrongBuy$108.4B5.74%28.5065.17%1.25%
See all

Stock Returns calculator for Co-Diagnostics Stock including INR - Dollar returns

The Co-Diagnostics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Co-Diagnostics investment value today

Current value as on today

₹6,773

Returns

-₹93,227

(-93.23%)

Returns from Co-Diagnostics Stock

-₹93,743 (-93.74%)

Dollar Impact

₹516 (+0.52%)

Analyst Recommendation on Co-Diagnostics Stock

Based on 6 analysts

HOLD

0.00%

Buy

50.00%

Hold

50.00%

Sell

Based on 6 analysts, 50% of analysts recommend a 'HOLD' rating for Co-Diagnostics. Average target price of $4

Co-Diagnostics Share Price Target

Get share price movements and forecasts by analysts on Co-Diagnostics.

What analysts predicted

82%UPSIDE

Target Price

$4

Current Price

$0.72

Analyzed by

6 Analysts

Target

$4.00

Co-Diagnostics target price $4, a slight upside of 82% compared to current price of $0.72. According to 6 analysts rating.

Indian Investors' Interest in Co-Diagnostics Stock

Search interest for Co-Diagnostics Stock has increased by 11% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:11% versus previous 30 day period

Co-Diagnostics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
2
0
0
0
0
0
0
0
0
Gross Profit
0
2
0
0
0
0
0
0
0
0
Operating Income
-10
-7
-10
-11
-8
-8
-7
-7
-9
-6
EBITDA
-8
-7
-9
-10
-7
-7
-6
-25
-8
-5
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-9
-7
-9
-11
-7
-7
-7
-26
-9
-6
Income Tax Expense
0
0
0
0
0
0
-1
0
0
0
Net Income
-9
-7
-9
-11
-7
-7
-5
-25
-9
-6
Net Profit Margin
7.22%
92.02%
53.61%
-70.81%
57.06%
80.29%
81.92%
46.05%
-207.78%
72.73%

Co-Diagnostics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Mar 2019
Mar 2020
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
0
0
74
97
34
6
3
0
Gross Profit
0
0
0
57
86
28
2
2
0
Operating Income
-4
-6
-5
41
46
-26
-42
-40
-31
EBITDA
-6
-6
-6
41
45
-10
-36
-36
-47
Interest Expense
0
0
0
-
-
-
-
-
-
Depreciation
0
0
0
0
0
1
1
1
1
Income Before Tax
-6
-6
-6
42
45
-18
-38
-37
-48
Income Tax Expense
-
0
-
0
8
-4
-2
0
-1
Net Income
-6
-6
-6
42
36
-14
-35
-37
-46
Net Profit Margin
96.06%
76.47%
47.70%
77.75%
88.18%
83.98%
38.57%
74.48%
64.28%

Co-Diagnostics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-9
-7
-9
-11
-7
-7
-5
-25
-9
-6
Operating Cash Flow
-8
-5
-7
-8
-8
-8
-5
-6
-7
-7
Investing Cash Flow
16
-4
4
0
7
17
2
0
0
0
Financing Cash Flow
-
-
-
0
0
0
4
6
4
2
Change in Cash
8
-9
-3
-7
-1
9
0
0
-3
-4

Co-Diagnostics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Mar 2019
Mar 2020
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-6
-6
-6
42
36
-14
-35
-37
-46
Operating Cash Flow
-3
-4
-5
28
41
6
-22
-29
-29
Investing Cash Flow
0
0
0
-5
4
-58
15
17
26
Financing Cash Flow
5
1
5
19
0
-14
-1
0
11
Change in Cash
2
-2
0
42
45
-65
-8
-11
8

Global Institutional Holdings in Co-Diagnostics

Check out the Institutions with significant holdings in Co-Diagnostics.

Funds
Holdings
Vanguard
0.78%
Bridgeway Funds, Inc.
0.44%
Victory Portfolios III
0.05%
Fidelity Concord Street Trust
0.00%

Co-Diagnostics News & Key Events

  • img

    Today's Timeline - 16 September

    Wed, 06:20 PM

    -

    Co-Diagnostics partners with ReadyGo Diagnostics for blood-based PCR testing, focusing on decentralized Ebola detection.

Insights on Co-Diagnostics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -25.74M → -6.28M (in $), with an average increase of 113.6% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 145.95K → 166.13K (in $), with an average increase of 12.2% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Edwards Lifesciences Corp has given 18.5% return, outperforming this stock by 111.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Medtronic plc has given 22.1% return, outperforming this stock by 119.7%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, CODX stock has moved down by -29.9%

About Co-Diagnostics

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
OrganisationCo-Diagnostics
Headquarters2401 S. Foothill Dr., Salt Lake City, UT, 84109, US
IndustryBiotechnology
CEODwight Egan

Key Management of Co-Diagnostics

Name

Title

Mr. Richard David Abbott

President

Mr. Seth Egan

Chief Commercialization Officer & Strategy Officer

Mr. Dwight H. Egan

Chairman, CEO & President

Mr. Dan Bohrer CPA

Executive VP of Finance & Accounting and Principal Financial & Accounting Officer

Mr. David Nielsen

Chief Operating Officer

Mr. Christopher Thurston

Chief Technology Officer

Dr. Wesley C. Lindsey MBA, Ph.D.

Chief Scientific Officer

Mr. Andrew Benson

Head of Investor Relations

Dr. Mayuranki Almaula Ph.D.

Senior Vice President of Overseas Operations & Strategic Alliances

FAQs

What is Co-Diagnostics share price today?

Co-Diagnostics share price today is $0.72 as on at the close of the market. Co-Diagnostics share today touched a day high of $0.81 and a low of $0.72.

What is the 52 week high and 52 week low for Co-Diagnostics share?

Co-Diagnostics share touched a 52 week high of $46.50 on and a 52 week low of $0.75 on . Co-Diagnostics stock price today i.e. is closed at $0.72,which is 98.45% down from its 52 week high and -3.49% up from its 52 week low.

What is Co-Diagnostics's market capitalisation today?

Co-Diagnostics market capitalisation is $0.00T as on .

How to invest in Co-Diagnostics Stock (CODX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Co-Diagnostics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Co-Diagnostics Stock (CODX) from India?

Indian investors can start investing in Co-Diagnostics (CODX) shares with as little as ₹95.05500030517578 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹950.55 in Co-Diagnostics stock (as per the Rupee-Dollar exchange rate as on ). Based on Co-Diagnostics share’s latest price of $0.72 as on October 16, 2026 at 1:29 am IST, you will get 13.8889 shares of Co-Diagnostics. Learn more about fractional shares .

What are the returns that Co-Diagnostics has given to Indian investors in the last 5 years?

Co-Diagnostics stock has given -99.7% share price returns and 27.65% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?